Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Most Read

  1. Checkpoint inhibitors continue to show benefits in a range of tumours
  2. Clinical trials for oncology biosimilars: for which indications can we expect approvals?
  3. Yervoy’s expanded indication will advance treatment for paediatric melanoma patients
  4. Novaliq’s NovaTears+Omega-3 represents the first-in-class omega-3-containing eye drop for evaporative dry eye
  5. Varubi IV’s second-try FDA approval provides CINV patients with a new option

Latest Content

Clinical trials for oncology biosimilars: for which indications can we expect approvals?

Over the past few years, biosimilars have been a hot topic in autoimmunity, and development has recently gained significant momentum in the oncology sector. With the first biosimilar approvals in oncology won in 2017, GlobalData expects this topic to gain significant attention in the year to come. While many questions regarding pricing, reimbursement, uptake, and acceptance among patients and oncologists are yet to be answered, the FDA and EMA guidelines on product development and approval have made significant progress in recent years.

Latest News

Read our magazine

Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.

Send me notifications of new editions:

Go Top